

KNOW THE FACTS ABOUT SPINOCEREBELLAR ATAXIA AND A NEW CLINICAL STUDY

About Spinocerebellar Ataxia (SCA)

SCA is an inherited form of ataxia, a rare and progressive neurological disease that develops due to damage to the cerebellum, the part of the brain responsible for coordinating movement.



Ataxia affects nearly 150,000 people living in the U.S. of which an estimated 3,200–18,000 have SCA



Symptoms of SCA may include lack of coordination, trouble with balance, difficulty swallowing, slurred speech and/or deterioration of fine motor skills



The most common types of SCA are SCA1, SCA2, SCA3, SCA6 and SCA7 which are caused by specific genetic defects



People are typically diagnosed in their mid-30s but SCA can affect all ages, genders and race



There is no cure or FDA-approved treatment for SCA



Current treatment approaches focus on symptom management to improve quality of life

SCA Study Overview

The Phase 3 randomized, controlled study is designed to evaluate troriluzole, an investigational drug that modulates the brain chemical glutamate. Brain cells communicate with each another by using chemicals, such as glutamate.



Participants are enrolled in the study for 48 weeks*

* Participants who participate in the study will be eligible to continue for an additional 48 week phase where all participants receive troriluzole.



Participants are randomized one-to-one on troriluzole or placebo and take two pills once daily



More than 18 U.S. medical centers are participating in the study



Mainly focus on disease-types SCA1 and SCA2



Study will measure if troriluzole can slow down and improve ataxia symptoms in people with SCA



Primary endpoint = measurable change in ataxia symptoms, including walking, standing, sitting and speech

Key Eligibility Criteria

- ✓ Known or suspected diagnosis of SCA1 or SCA2
- ✓ Confirmed clinical evidence of SCA diagnosis or willingness to have testing completed
- ✓ Ability to walk eight meters without human assistance (canes or other devices are allowed)
- ✓ Be physically able to complete the trial (adequate hearing, vision and language skills)

For more information about this study, visit www.scatrial.org

The study is sponsored by Biohaven Pharmaceuticals.

